VAB, which we developed and launched with Validus Pharmaceuticals, encourages and enables physician participation and communication through a variety of moderated comment and discussion tools within featured content pages. The first feature program is a four-part video series focusing on the unmet needs in Bipolar I. The presenters discuss the treatment of Bipolar I using the drug carbamazepine, and how carbamazepine evolved from discovery and clinical trials into the FDA-approved formulation, Equetro, that is used in clinical practice today.

Featured emerging scientific issues and clinical information are conveniently organized and updated on a weekly basis. OurCreatus.org offers an inside view of Amylin’s cutting-edge approaches to discovery, research and development and the scientists who are making it happen.

We believe that you are never too old to want to play with robots, let alone watch them go head to head in battle. Once the battle and its contenders are defined, knowing the outcome is crucial to the physicians in order to make sure they are giving their patients the most effective artillery to generate an individual victory.

This creative approach of applying youthful fascination to the traditional pharmaceutical physician outreach material is how we intend to differentiate our client from the rest of the robotic operations in the market.

We’ve been working with them for two years as part of a multi-agency partnership to develop and manage the company’s relationships with key industry opinion leaders (prominent practicing and academic physicians that are heavily involved in scientific research, clinical trial investigation, and who speak and write extensively on developments in these disease areas).

The cornerstone of our program is a magnet web property known as “CREATUS” (the Latin for “to create”). It’s a members-only portal rich in scientific media and other resources, delivering breaking news, clinical information and the latest discovery research from every legitimate outlet around the globe – not just from Amylin. Unique in its non-promotional tone and democratic approach to inclusion of industry-wide content, we think it will become the new model for building strong physician relationships in the post-advertising era we’re living in today.

Crazy is cruel. It’s a massively misplaced label that’s insensitive to the incredible pain and suffering of people afflicted with these disorders. It minimizes the reality of the chemical origins of mental illness, and in doing so it marginalizes the victims.

Our job for Validus’ Equetro brand (and its sister product, Marplan) is to manage an ongoing educational series of eCRM communications aimed at current and prospective physician-prescribers that treat patients with depression and bipolar disorders. While the product is not new, knowledge of its efficacy has historically been very limited because the brand isn’t widely advertised or promoted. So a targeted physician recruitment and communications effort makes perfect sense, and ultimately that helps people when they’re able to get onto an appropriate form of treatment.